Literature DB >> 21770923

CDKL5 alterations lead to early epileptic encephalopathy in both genders.

Jao-Shwann Liang1, Keiko Shimojima, Rumiko Takayama, Jun Natsume, Minobu Shichiji, Kyoko Hirasawa, Kaoru Imai, Tohru Okanishi, Seiji Mizuno, Akihisa Okumura, Midori Sugawara, Tomoshiro Ito, Hiroko Ikeda, Yukitoshi Takahashi, Hirokazu Oguni, Katsumi Imai, Makiko Osawa, Toshiyuki Yamamoto.   

Abstract

PURPOSE: Genetic mutations of the cyclin-dependent kinase-like 5 gene (CDKL5) have been reported in patients with epileptic encephalopathy, which is characterized by intractable seizures and severe-to-profound developmental delay. We investigated the clinical relevance of CDKL5 alterations in both genders.
METHODS: A total of 125 patients with epileptic encephalopathy were examined for genomic copy number aberrations, and 119 patients with no such aberrations were further examined for CDKL5 mutations. Five patients with Rett syndrome, who did not show methyl CpG-binding protein 2 gene (MECP2) mutations, were also examined for CDKL5 mutations. KEY
FINDINGS: One male and three female patients showed submicroscopic deletions including CDKL5, and two male and six female patients showed CDKL5 nucleotide alterations. Development of early onset seizure was a characteristic clinical feature for the patients with CDKL5 alterations in both genders despite polymorphous seizure types, including myoclonic seizures, tonic seizures, and spasms. Severe developmental delays and mild frontal lobe atrophies revealed by brain magnetic resonance imaging (MRI) were observed in almost all patients, and there was no gender difference in phenotypic features. SIGNIFICANCE: We observed that 5% of the male patients and 14% of the female patients with epileptic encephalopathy had CDKL5 alterations. These findings indicate that alterations in CDKL5 are associated with early epileptic encephalopathy in both female and male patients. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770923     DOI: 10.1111/j.1528-1167.2011.03174.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  21 in total

1.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.

Authors:  Stephanie Fehr; Meredith Wilson; Jenny Downs; Simon Williams; Alessandra Murgia; Stefano Sartori; Marilena Vecchi; Gladys Ho; Roberta Polli; Stavroula Psoni; Xinhua Bao; Nick de Klerk; Helen Leonard; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2012-08-08       Impact factor: 4.246

Review 2.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

Authors:  Heather E Olson; Scott T Demarest; Elia M Pestana-Knight; Lindsay C Swanson; Sumaiya Iqbal; Dennis Lal; Helen Leonard; J Helen Cross; Orrin Devinsky; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-02-23       Impact factor: 3.372

3.  Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications.

Authors:  Przemyslaw Szafranski; Sailaja Golla; Weihong Jin; Ping Fang; Patricia Hixson; Reuben Matalon; Daniel Kinney; Hans-Georg Bock; William Craigen; Janice L Smith; Weimin Bi; Ankita Patel; Sau Wai Cheung; Carlos A Bacino; Paweł Stankiewicz
Journal:  Eur J Hum Genet       Date:  2014-10-15       Impact factor: 4.246

4.  Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice.

Authors:  I-Ting Judy Wang; Megan Allen; Darren Goffin; Xinjian Zhu; Andrew H Fairless; Edward S Brodkin; Steve J Siegel; Eric D Marsh; Julie A Blendy; Zhaolan Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

Review 5.  Genetics, molecular biology, and phenotypes of x-linked epilepsy.

Authors:  Hao Deng; Wen Zheng; Zhi Song
Journal:  Mol Neurobiol       Date:  2013-11-22       Impact factor: 5.590

6.  Exploring the genetic etiology of drug-resistant epilepsy: incorporation of exome sequencing into practice.

Authors:  Mojdeh Mahdiannasser; Ali Rashidi-Nezhad; Reza Shervin Badv; Seyed Mohammad Akrami
Journal:  Acta Neurol Belg       Date:  2022-09-21       Impact factor: 2.471

7.  Copy number variation plays an important role in clinical epilepsy.

Authors:  Heather Olson; Yiping Shen; Jennifer Avallone; Beth R Sheidley; Rebecca Pinsky; Ann M Bergin; Gerard T Berry; Frank H Duffy; Yaman Eksioglu; David J Harris; Fuki M Hisama; Eugenia Ho; Mira Irons; Christina M Jacobsen; Philip James; Sanjeev Kothare; Omar Khwaja; Jonathan Lipton; Tobias Loddenkemper; Jennifer Markowitz; Kiran Maski; J Thomas Megerian; Edward Neilan; Peter C Raffalli; Michael Robbins; Amy Roberts; Eugene Roe; Caitlin Rollins; Mustafa Sahin; Dean Sarco; Alison Schonwald; Sharon E Smith; Janet Soul; Joan M Stoler; Masanori Takeoka; Wen-Han Tan; Alcy R Torres; Peter Tsai; David K Urion; Laura Weissman; Robert Wolff; Bai-Lin Wu; David T Miller; Annapurna Poduri
Journal:  Ann Neurol       Date:  2014-06-13       Impact factor: 10.422

8.  CDKL5 and ARX mutations in males with early-onset epilepsy.

Authors:  Ghayda M Mirzaa; Alex R Paciorkowski; Eric D Marsh; Elizabeth M Berry-Kravis; Livija Medne; Asem Alkhateeb; Art Grix; Elaine C Wirrell; Berkley R Powell; Katherine C Nickels; Barbara Burton; Andrea Paras; Katherine Kim; Wendy Chung; William B Dobyns; Soma Das
Journal:  Pediatr Neurol       Date:  2013-05       Impact factor: 3.372

9.  Brain morphological abnormalities in children with cyclin-dependent kinase-like 5 deficiency disorder.

Authors:  Yingying Tang; Zhong Irene Wang; Shaheera Sarwar; Joon Yul Choi; Shan Wang; Xiaoming Zhang; Sumit Parikh; Ahsan N Moosa; Elia Pestana-Knight
Journal:  Eur J Paediatr Neurol       Date:  2021-02-15       Impact factor: 3.140

Review 10.  What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.

Authors:  Charlotte Kilstrup-Nielsen; Laura Rusconi; Paolo La Montanara; Dalila Ciceri; Anna Bergo; Francesco Bedogni; Nicoletta Landsberger
Journal:  Neural Plast       Date:  2012-06-17       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.